Atara Bounces Back with FDA
Atara Biotherapeutics saw its shares nearly double on May 7 after the FDA outlined a path for resubmitting its cell‑therapy candidate, tabelecleucel. The agency agreed to accept the single‑arm trial data in exchange for additional long‑term follow‑up, easing the regulatory deadlock that followed two prior rejections. The stock closed at $9.93, up 93%, and later rebounded to $10.48 after earnings, though still below its pre‑rejection $14‑$18 range. Atara projects a cash runway through mid‑2027, bolstered by a $4.8 million equity raise and aggressive cost cuts.
MSD's Sac-TMT Delivers in First Phase 3 Readout
Merck (MSD) reported that its TROP2‑targeting antibody‑drug conjugate sacituzumab tirumotecan (sac‑TMT), licensed from China’s Kelun‑Biotech, improved progression‑free and overall survival in a phase 3 trial for advanced or recurrent endometrial cancer. The TroFuse‑005 readout marks the first pivotal data for sac‑TMT...
Merck's ADC Sac-TMT Gets Its First Global Phase 3 Win Ahead of Schedule
Merck and China‑based Kelun‑Biotech announced that their experimental antibody‑drug conjugate sac‑TMT achieved its primary endpoint in a global Phase 3 trial, completing ahead of schedule. The study enrolled roughly 650 patients with advanced solid tumours across 12 countries and demonstrated a...
Sotatercept Reduced Morbidity in CTD-PAH Analysis: Rogerio Souza, MD, PhD
A pooled analysis of the phase‑3 STELLAR, ZENITH and HYPERION trials shows that sotatercept significantly lowers the risk of first major morbidity or mortality events in patients with connective tissue disease‑associated pulmonary arterial hypertension (CTD‑PAH). The benefit persisted despite most...
FDA Approves Baxdrostat for Inadequately Controlled Hypertension
AstraZeneca’s Baxdrostat (Baxfendy) received FDA approval as the first aldosterone synthase inhibitor for hypertension in the United States. The drug is indicated for patients whose blood pressure remains uncontrolled despite taking at least two other antihypertensive agents. Phase III trials (BaxHTN...
What Comes After Pluvicto? A New and Distinct Prostate Cancer Patient Subpopulation Is Taking Shape
PSMA‑targeted radioligand therapy, exemplified by lutetium‑177 vipivotide tetraxetan (Pluvicto), is now a standard option for metastatic castration‑resistant prostate cancer. However, response durability is limited, with fewer than half of patients achieving meaningful benefit and most eventually progressing. The authors highlight...
Pittsburgh Researchers Develop Shelf-Stable Artificial Platelets to Stop Severe Bleeding
Researchers at the University of Pittsburgh, in partnership with Case Western Reserve and Haima Therapeutics, have created SynthoPlate, a freeze‑dried artificial platelet that reconstitutes with water to form a clotting agent. The quarter‑sized vial remains stable at room temperature for...
STAT+: Pharmalittle: We’re Reading About U.S. Biotech’s China Problem, a Regeneron Flop, and Much More
U.S. biotech companies have poured roughly $60 billion into Chinese‑origin molecules in the first quarter of 2026, a rate that could double the previous year’s spend and is ten times the 2021 level. The surge is deepening a split in the...
The Ebola Emergency Shines a Light on the Urgent Need for New Vaccines
The Democratic Republic of Congo and Uganda are facing a Bundibugyo Ebola outbreak, with the U.S. CDC reporting 336 suspected cases and 88 deaths as of 17 May. The WHO declared a public‑health emergency of international concern, but its response is...
How Advanced Analytics Partnerships Enhance the Biopharma Value Chain
Strategic biopharma alliances are increasingly embedding multimodal AI across the entire drug‑development pipeline. Partnerships leverage foundation models to sharpen biomarker discovery and patient selection for complex modalities such as antibody‑drug conjugates. Large‑scale genomic and clinical datasets enable virtual cell modeling...
Novartis Reveals More Data Behind Pluvicto Expansion Bid
Novartas reported new PSMAddition trial data showing that adding its radioligand therapy Pluvicto to standard hormonal treatment cuts PSA progression by 58% in hormone‑sensitive metastatic prostate cancer. Deep PSA reductions below 0.2 ng/mL were achieved by 87.4% of patients versus 74.9%...
Amgen’s Rare Disease Drug Tavneos Tied to 20 Deaths in Japan
Amgen’s rare‑disease drug Tavneos has been linked to 20 deaths among roughly 8,500 Japanese patients, primarily due to vanishing bile duct syndrome, a severe form of drug‑induced liver injury. The Japanese distributor Kissei Pharmaceutical has warned doctors against initiating new...
Regeneron Inks a ~$2.3B Deal with Parabilis Medicines to Advance Antibody-Helicon Conjugates Across Multiple Therapeutic Areas
Regeneron has struck a strategic research collaboration with Parabilis Medicines to develop antibody‑Helicon conjugates (AHCs) across several therapeutic areas. The agreement provides Parabilis with $125 million, including $50 million upfront and a $75 million equity‑financing commitment, and makes it eligible for roughly $2.2 billion...
Harbour Posts Preclinical Data on Would-Be Rival to Eli Lilly’s $1.9B Obesity Bet
Harbour BioMed released preclinical data on LET003, an ACVR2A/2B‑targeting monoclonal antibody created with its AI‑enabled Hu‑mAtrIx platform. In mouse and monkey studies the molecule cleared more slowly than comparators and drove a 13.5% increase in lean mass versus a rival...
BIO Supports and Seeks Refinements to FDA’s Plausible Mechanism Framework
The FDA has issued draft guidance introducing a Plausible Mechanism Framework to evaluate safety and efficacy of individualized, disease‑targeted therapies when traditional trials are infeasible. The Biotechnology Innovation Organization (BIO) issued a supportive comment letter, praising the agency’s direction while...
Supercharging Immune Cells May Help Control HIV Long-Term
Scientists have repurposed CAR‑T cell therapy, originally used for cancer, to target HIV. In a small Phase 1 trial, two participants who received the engineered T cells remained off antiretroviral drugs with undetectable viral loads for nearly two years and one...
AstraZeneca Reports the US FDA Approval of Baxfendy (Baxdrostat) To Treat Hard-to-Control Hypertension
AstraZeneca’s Baxfendy (baxdrostat) received U.S. FDA approval for use with other antihypertensives in patients with uncontrolled or treatment‑resistant hypertension. The approval is based on the Phase III BaxHTN trial, which enrolled 796 participants and showed significant blood‑pressure reductions versus placebo. In...
Japan’s MHLW Approves Boehringer’s Jascayd for IPF and PPF
Boehringer Ingelheim’s Jascayd (nerandomilast) has been approved by Japan’s Ministry of Health, Labour and Welfare for treating idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). It is the first phosphodiesterase 4B inhibitor with antifibrotic and immunomodulatory properties to receive such...
Lotte Biologics Expands Antibody Manufacturing Agreement with Ottimo Pharma
Lotte Biologics announced on May 18, 2026 an expanded collaboration with South Korean biotech Ottimo Pharma to manufacture its PD‑1/VEGFR2 dual‑paratopic antibody, OTP‑01. The agreement builds on a June‑2025 deal and adds commercial process development support at Lotte’s Syracuse Bio Campus in...
STAT+: The China Question Is Tearing Biotech Apart
U.S. biotech firms have poured roughly $60 billion into Chinese‑origin molecules in the first quarter of 2026, a rate that could double the previous year’s spend and represents a ten‑fold jump since 2021. The influx of affordable, fast‑developed compounds fuels pipeline...
Genentech Reports FDA Approval of Tecentriq and Tecentriq Hybreza for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment
Genentech’s Tecentriq and Tecentriq Hybreza received FDA approval as adjuvant therapies for adults with muscle‑invasive bladder cancer (MIBC) who show circulating tumor DNA (ctDNA) minimal residual disease after cystectomy. The approval is linked to Natera’s Signatera CDx assay, which was...
Spatially Tunable Multiomic Sequencing Using Light-Driven Combinatorial Barcoding of Molecules in Tissues
Researchers introduced Barcoding by Activated Linkage of Indexes (BALI), a light‑driven combinatorial barcoding platform that writes spatial DNA barcodes directly onto diverse biomolecules in tissue sections. The technique lets users define the number, size, shape and resolution of regions, enabling...
Can Revolution’s 'Miracle' Pancreatic Cancer Drug Be Topped? Immuneering, Actuate Say Yes
Revolution Medicines reported Phase 3 data showing its oral RAS inhibitor daraxonrasib more than doubled median overall survival for advanced pancreatic cancer to 13.2 months versus 6.7 months on chemotherapy. The results triggered a 40 % share surge and will support global regulatory filings,...
4 Spaces Primed for the Next Wave of Gene Therapies
The FDA’s recent approval of Regeneron’s Otarmeni for hereditary hearing loss marks the first non‑oncology gene‑therapy clearance, underscoring a shift toward treating central‑nervous‑system, ophthalmic, cardiovascular and muscular disorders. Companies such as Lexeo, Lilly/AskBio, uniQure, REGENXBIO/AbbVie, Tenaya, Medera and Sarepta are...
This Startup Aims to Upend Biologic Drug Production With Implantable ‘Cell Factories’
Duracyte, a Rice‑University spin‑out, is developing an implantable "cell factory" that produces therapeutic proteins inside patients, eliminating the need for traditional biologic manufacturing and injection pens. The capsule‑sized device houses genetically engineered human cells, supplies them with nutrients from the...
Cas9+ Conditionally Immortalized Neutrophil Progenitors as a Tool for Genome Wide CRISPR Screening for Neutrophil Differentiation and Function
Researchers at UC Berkeley have engineered a Cas9‑expressing, estrogen‑regulated Hoxb8 neutrophil progenitor line that can be genetically edited and differentiated into functional neutrophils both in vitro and in vivo. The platform enables forward and reverse genetics, demonstrated by a pooled...
AI Tool in Radiotherapy Advances Global Fight to Eradicate Cervical Cancer
A collaborative consortium has launched an AI‑driven radiotherapy planning platform that automates contouring and dose‑optimization for cervical cancer. Trained on more than 10,000 patient scans, the tool generates treatment plans in minutes, cutting planning time by roughly 40% while preserving...
Alcolase Raises €1.5M to Tackle Alcohol Intolerance with Enzyme Technology
Danish biotech Alcolase secured €1.5 million (about $1.6 million) from investors including Ada Ventures, Delphinus VC, Antler and angel groups. The startup is developing a liposome‑encapsulated enzyme that breaks down alcohol in the stomach, aiming to help the roughly 540 million East Asians...
Weight-Loss Drugs Tied to Lower Death, Recurrence Risk After Breast Cancer
A retrospective cohort study of more than 840,000 breast‑cancer patients diagnosed between 2006 and 2023 found that use of GLP‑1 receptor agonists—drugs approved for type‑2 diabetes and obesity—was associated with a lower risk of death and cancer recurrence over a...
Study Maps Brain Immune Cells to Block Melanoma Metastasis
Yale researchers are targeting the brain's native immune cells to stop melanoma from forming deadly brain metastases. Their work focuses on the IL‑4 signaling axis, which overactivates myeloid cells and creates a pre‑metastatic niche that shields tumor cells from standard...
Synthesis and In-Vitro Cytotoxicity Evaluation of 1,2,3-Triazole Incorporated 1,3,4- Oxadiazole-Imidazole-Pyridine Derivatives as Anticancer Agents
Researchers synthesized a novel series of 1,2,3‑triazole‑incorporated 1,3,4‑oxadiazole‑imidazole‑pyridine compounds (27a‑j) and characterized them fully. In vitro cytotoxicity testing against MCF‑7, A549, Colo‑205 and A2780 cell lines showed that three analogues—27a, 27b and 27i—outperformed the reference drug etoposide. Compound 27a was...
Overactive MYC Helps Tumors Fix DNA Breaks and Resist Chemotherapy, Study Finds
Researchers at Oregon Health & Science University discovered that the oncogene MYC, long known for driving tumor growth, also directly repairs DNA breaks in cancer cells. The study, published in Genes & Development, shows a modified form of MYC relocating...
New Blood Test Detects Tumor DNA to Guide Treatment in Advanced Cancer Cases
A new circulating tumor DNA (ctDNA) blood test received FDA clearance to guide therapy for patients with advanced solid tumors. The assay demonstrates 95% sensitivity across 12 cancer types and can pinpoint actionable mutations within seven days. Priced at roughly...
Why J&J Thinks Its New Psoriasis Pill Could Be One of Its Biggest Drugs Ever
Johnson & Johnson’s newly approved oral psoriasis pill Icotyde targets the IL‑23 receptor, making it the first once‑daily tablet in a class dominated by injectables. The drug entered the market in March and logged roughly 1,500 prescriptions within its first...
Student-Built System Unlocks Fully Autonomous Electroporation for 96- and 384-Well Workflows
At UCLA’s Living Biofoundry, two students engineered a fully autonomous version of the Fisher Scientific BTX Gemini X2 electroporator, enabling 96‑ and 384‑well plate workflows without human intervention. They built a custom software bridge to communicate with the instrument’s proprietary...
Researchers Identify First Suite of Human Antibodies Against Measles Virus
NIH‑funded researchers have isolated and structurally mapped the first comprehensive set of human monoclonal antibodies against measles virus, revealing nine distinct epitopes on the H and F surface proteins. One antibody, 4F09, locked the fusion protein and cleared virus from...
FDA Approves Two Separate Indications for Fam-Trastuzumab Deruxtecan-Nxki in HER2-Positive Early-Stage Breast Cancer
The FDA has approved fam‑trastuzumab deruxtecan‑nxki (Enhertu) for two new indications in HER2‑positive early‑stage breast cancer: a neoadjuvant regimen followed by taxane, trastuzumab and pertuzumab, and an adjuvant regimen for patients with residual invasive disease. In the DESTINY‑Breast11 neoadjuvant trial,...
The BioPharm Brief: Oncology Momentum, CAR-T Advances, Strategic Expansion
AstraZeneca’s exploratory POTOMAC trial showed that combining its checkpoint inhibitor Imfinzi with BCG lowered early recurrence risk in patients with high‑risk non‑muscle‑invasive bladder cancer. At ASGCT 2026, Imviva presented early remission data from an allogeneic CAR‑T platform targeting lupus, hinting at...
A Big Year for Ionis
Ionis Pharmaceuticals, a pioneer in antisense oligonucleotide (ASO) therapeutics, is transitioning from a licensing‑focused model to directly commercializing its own drugs. The breakthrough approval of Spinraza for spinal muscular atrophy validated the ASO approach and unlocked a pipeline of both...
FDA Approves First Interchangeable Biosimilars to Simponi and Simponi Aria (Golimumab) to Treat Rheumatoid Arthritis and Ulcerative Colitis
The FDA has approved Immgolis (golimumab‑sldi) and Immgolis Intri as interchangeable biosimilars to Janssen’s Simponi and Simponi Aria, respectively. Immgolis is delivered via a prefilled subcutaneous syringe, while Immgolis Intri is given as an intravenous infusion. Both are indicated for adults...
Antiviral Ensitrelvir Cuts Risk of COVID-19 in Household Contacts by Two-Thirds, Study Finds
A Phase III trial published in the New England Journal of Medicine shows that the oral antiviral ensitrelvir, given within 72 hours of an index case’s symptom onset, cuts the risk of symptomatic COVID‑19 in household contacts by roughly two‑thirds. The study...
Single-Molecule RNA Mapping May Reveal How Shape Shifts Steer Health and Disease
Researchers at Singapore’s A*STAR Genome Institute have unveiled “sm‑PORE‑cupine,” a technique that combines chemical labeling with nanopore direct RNA sequencing to map RNA structures at single‑molecule resolution. The approach tags non‑paired bases, enabling full‑length reads that expose how individual transcripts...
Multi-Institutional Trial Explores New Lifeline for Advanced Prostate Patients
Researchers at MUSC and Emory reported Phase 2 results for opaganib, an oral drug targeting sphingolipid metabolism, added to standard androgen‑receptor therapies in metastatic castration‑resistant prostate cancer. In 66 patients, disease control at 16 weeks reached 15% with abiraterone and 9% with...
Implantable Bacteria Can Now Be Safely Contained, Clearing a Major Hurdle for Fighting Infection and Cancer
Harvard researchers have engineered a polyvinyl alcohol (PVA) hydrogel scaffold that securely contains therapeutic bacteria for up to six months, preventing escape while allowing drug‑release functions. The scaffold’s stiffness and toughness give it a ten‑fold higher fatigue threshold than prior...
ASGCT Q1 Landscape Report Paints Positive Picture for Gene and RNA Therapy
The American Society for Gene and Cell Therapy (ASGCT) released its Q1 2026 Landscape Report, noting 42 gene, 38 RNA and 76 cell therapies have received regulatory approval worldwide. Startup funding surged 30% year‑over‑year, with 26 new companies entering the...
Rogue Antibodies Drive Tau Pathology
Researchers at DZNE and Charité have demonstrated that patient‑derived anti‑IgLON5 antibodies directly cause neuronal hyperactivity, which in turn drives the mislocalization and toxic aggregation of Tau proteins. Experiments in cultured neurons and wild‑type mice showed IgLON5 clustering on the cell...
ECO 2026: Indirect Comparison Favours Wegovy Pill over Foundayo
At the 33rd European Congress on Obesity, Novo Nordisk presented a post‑hoc indirect comparison of oral semaglutide (Wegovy pill) versus orforglipron (Foundayo). Using simulated treatment comparison and matching‑adjusted indirect methods, the analysis showed Wegovy achieved roughly 3 percentage‑points greater weight...
New mRNA Therapy Destroys Cancer by Improving T Cell Priming
MIT researchers engineered lipid‑nanoparticle mRNA encoding NF‑κB‑inducing kinase (NIK) or IRF8 to reprogram immature dendritic cells into the cDC1 phenotype. The immune‑remodeling mRNAs amplified CD8+ T‑cell priming, leading to complete tumor regression in 70‑80% of mice across colorectal and metastatic...
Candel Reports Prostate Cancer Drug's Long-Term Data Ahead of FDA Filing
Candel Therapeutics released long‑term follow‑up results for its investigational prostate cancer therapy, showing durable efficacy and a favorable safety profile. The data reveal a 78% five‑year disease‑free survival rate and a median PSA decline of over 90% in the majority...
Aardvark's Next Move After Clinical Hold; Alumis' Verdict on Acelyrin Asset
Aardvark Therapeutics announced that the FDA clinical hold on its rare‑disease HERO and OLE studies has been lifted, allowing the company to unblind the trial data. The unblinding will provide critical efficacy and safety readouts for the targeted condition. In...